Literature DB >> 8418240

Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer.

A L Abner1, A Recht, T Eberlein, S Come, L Shulman, D Hayes, J L Connolly, S J Schnitt, B Silver, J R Harris.   

Abstract

PURPOSE: The prognosis and factors that influence prognosis following salvage mastectomy in patients with recurrence in the treated breast after conservative surgery (CS) and radiation therapy (RT) were investigated.
MATERIALS AND METHODS: A total of 1,593 patients with stage I or II invasive breast cancer were treated following gross total excision of the tumor at the Joint Center for Radiation Therapy (JCRT) between 1968 and 1985. One hundred sixty-six of the 1,593 (10%) had subsequent recurrence in the breast. Of these, 123 had salvage mastectomy and constitute the study population. The recurrent tumor was predominantly invasive in 99 patients, noninvasive in 14, and focally invasive in 10. Following mastectomy, chemotherapy or hormonal therapy was administered to 29 patients. The median follow-up time was 39 months after salvage mastectomy.
RESULTS: The 5-year actuarial rate of further local or distant relapse for the entire group was 41%. None of the 24 patients with focally invasive or noninvasive tumors had a subsequent relapse. In comparison, the 5-year actuarial rate of further relapse in the 99 patients with a predominantly invasive recurrence was 52% (P = .001). The method of detection of the recurrence, the age of the patient at initial diagnosis, the disease-free interval, and the location of the recurrence in the breast were not found to have a statistically significant association with the risk of further relapse.
CONCLUSION: We conclude that the histology of the recurrent tumor is an important prognostic factor for the risk of further relapse. Patients with purely noninvasive or focally invasive tumors have an excellent prognosis following salvage mastectomy. In contrast, patients with predominantly invasive tumors are at substantial risk for further relapse.

Entities:  

Mesh:

Year:  1993        PMID: 8418240     DOI: 10.1200/JCO.1993.11.1.44

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

1.  Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.

Authors:  Chad G Rusthoven; Brian D Kavanagh; Sana D Karam
Journal:  Ann Transl Med       Date:  2015-07

2.  Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany.

Authors:  Sebastian Braun; Thomas Mittendorf; Thomas Menschik; Wolfgang Greiner; Johann-Matthias von der Schulenburg
Journal:  Breast Care (Basel)       Date:  2009-12-11       Impact factor: 2.860

Review 3.  Recent developments in breast-conserving surgery for breast cancer patients.

Authors:  F Fitzal; O Riedl; R Jakesz
Journal:  Langenbecks Arch Surg       Date:  2008-09-10       Impact factor: 3.445

4.  Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo.

Authors:  Stephanie M Cohen; Ridhwi Mukerji; Shuang Cai; Ivan Damjanov; M Laird Forrest; Mark S Cohen
Journal:  Am J Surg       Date:  2011-10-08       Impact factor: 2.565

5.  NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence.

Authors:  Douglas W Arthur; Kathryn A Winter; Henry M Kuerer; Bruce G Haffty; Laurie W Cuttino; Dorin A Todor; Nicole L Simone; Shelly B Hayes; Wendy A Woodward; Beryl McCormick; Randi J Cohen; Walter M Sahijdak; Daniel J Canaday; Doris R Brown; Adam D Currey; Christine M Fisher; Reshma Jagsi; Julia White
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-18       Impact factor: 7.038

6.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Authors:  Stefan Aebi; Shari Gelber; Stewart J Anderson; István Láng; André Robidoux; Miguel Martín; Johan W R Nortier; Alexander H G Paterson; Mothaffar F Rimawi; José Manuel Baena Cañada; Beat Thürlimann; Elizabeth Murray; Eleftherios P Mamounas; Charles E Geyer; Karen N Price; Alan S Coates; Richard D Gelber; Priya Rastogi; Norman Wolmark; Irene L Wapnir
Journal:  Lancet Oncol       Date:  2014-01-16       Impact factor: 41.316

Review 7.  Conservative surgery without radiotherapy in the treatment of patients with early-stage invasive breast cancer. A review.

Authors:  A Recht; M J Houlihan
Journal:  Ann Surg       Date:  1995-07       Impact factor: 12.969

Review 8.  Salvage surgery for recurrence after breast conservation.

Authors:  M P Osborne; R M Simmons
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

9.  Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.

Authors:  Irene L Wapnir; Stefan Aebi; Shari Gelber; Stewart J Anderson; István Láng; André Robidoux; Eleftherios P Mamounas; Norman Wolmark
Journal:  Ann Surg Oncol       Date:  2008-09-11       Impact factor: 5.344

10.  Local relapse after breast-conserving surgery and radiotherapy: effects on survival parameters.

Authors:  Josef Hammer; Christine Track; Dietmar H Seewald; Kurt J Spiegl; Johannes Feichtinger; Andreas L Petzer; Werner Langsteger; Sabine Pöstlberger; Elisabeth Bräutigam
Journal:  Strahlenther Onkol       Date:  2009-08-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.